Decreased survival after conversion to serum HER-2/neu positive.

被引：0
|
作者：
Lipton, A
Leitzel, K
Ali, SM
Demers, L
Harvey, HA
Chaudri-Ross, H
Lang, R
Hackl, W
Hamer, P
Carney, W
机构：
[1] W Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VA Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Oncogene Sci Bayer Diagnost, Cambridge, MA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [1] Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer
    Maltzman, J.
    Blackwell, K.
    Stein, S.
    Martin, A.
    Westland, R.
    Burstein, H.
    Gomez, H.
    Gartner, N.
    Platek, G.
    Newmiller, M.
    Lipton, A.
    Carney, W. P.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [2] Serum HER-2/neu testing can identify HER-2/neu positive patients previously classified as negative by tissue testing
    Carney, W. P.
    Brown-Shimer, S.
    Hamer, P. J.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [3] Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Evans, D
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    CANCER, 2005, 104 (02) : 257 - 263
  • [4] Automated assay for HER-2/neu in serum
    Payne, RC
    Allard, JW
    Anderson-Mauser, L
    Humphreys, JD
    Tenney, DY
    Morris, DL
    CLINICAL CHEMISTRY, 2000, 46 (02) : 175 - 182
  • [5] Monitoring therapy by serum HER-2/neu
    Schwartz, MK
    Smith, C
    Schwartz, DC
    Dnistrian, A
    Neiman, I
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (04): : 324 - 329
  • [6] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
  • [7] An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment.
    Mazouni, C.
    Hall, A.
    Anderson, K.
    Peintinger, F.
    Frische, H.
    Andre, F.
    Yekell, S.
    Arun, B.
    Buzdar, A. U.
    Esteva, F.
    Pusztai, L.
    Cristofanilli, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S51 - S51
  • [8] Profiling serum HER-2/NEU in prostate cancer
    Siampanopoulou, M.
    Galaktidou, G.
    Dimasis, N.
    Gotzamani-Psarrakou, A.
    HIPPOKRATIA, 2013, 17 (02) : 108 - 112
  • [9] Clinical value of serum HER-2/neu testing
    Luefner, D.
    Possinger, K.
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [10] Serum EGFr and HER-2/neu predicts poor survival in metastatic breast cancer
    Hamer, P. J.
    Jarosz, D. E.
    Leitzel, K.
    Ali, S. M.
    Demers, L.
    Evans, D. B.
    Chaudri-Ross, H. A.
    Lipton, A.
    Camey, W. P.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A168 - A168
12345